ANALISIS MOTIVASI MENGAJAR GURU ATAS IMPLEMENTASI KURIKULUM MERDEKA DI SMP BHINA DHARMA 2 KOTA BANDUNG

This research aims to measure the level of motivation of teacher due to the implementation of Kurikulum Merdeka at SMP Bhina Dharma 2 Bandung. This is considered important because majority teachers are still confuse and lack of understanding to implement Kurikulum Merdeka, leading a decreasing level of motivation to teach. Meanwhile, motivation is an essential factor to improve teacher’s ability in order to plan, practice, and assess the curriculum used at schools to obtain the best learning outcomes. Therefore, it is important to measure how the level of teacher’s motivation in teaching activity. This is a descriptive quantitative research with survey method, using questionnaire as the main instrument to reachout the purpose of the research. Further, this research used a total sampling technique, reaching 26 respondents. Then, the result revealed that teahers at SMP Bhina Dharma 2 Bandung have a good enough motivation to teach based on Kurikulum Merdeka implementation, reaching 67,31%. Further, this research also finds that there is a difference level of motivation among teachers which caused by the length of their experience as a teache

Elderly versus younger patients with hereditary angioedema type I/II: patient characteristics and safety analysis from the Icatibant Outcome Survey.

BACKGROUND: Hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) is characterized by recurrent swelling in subcutaneous or submucosal tissues. Symptoms often begin by age 5-11 years and worsen during puberty, but attacks can occur at any age and recur throughout life. Disease course in elderly patients is rarely reported. METHODS: The Icatibant Outcome Survey (IOS) is an observational study evaluating the safety, tolerability, and efficacy of icatibant. We conducted descriptive analyses in younger (age < 65 years) versus elderly patients (age ≥ 65 years). Here, we report patient characteristics and safety-related findings. RESULTS: As of February 2018, 872 patients with C1-INH-HAE type I/II were enrolled, of whom 100 (11.5%) were ≥ 65 years old. Significant differences between elderly versus younger patients, respectively, were noted for median age at symptom onset (17.0 vs 12.0 years), age at diagnosis (41.0 vs 19.4 years), and delay between symptom onset and diagnosis (23.9 vs 4.8 years) (P ≤ 0.0001 for all). Median age at diagnosis was significantly higher in elderly patients regardless of family history (P < 0.0001). Throughout the study, icatibant was used to treat 6798 attacks in 574 patients, with 63 elderly patients reporting 715 (10.5%) of the icatibant-treated attacks. No serious adverse events (SAEs) in elderly patients were judged to be possibly related to icatibant, whereas two younger patients reported three possibly related SAEs. Excluding off-label use and pregnancy (evaluated for regulatory purposes), the percentage of patients with at least one possibly/probably related AE was similar for elderly (2.0%) versus younger patients (2.7%). No deaths linked to icatibant treatment were identified. All related events in elderly patients were attributed to general disorders/administration site conditions, whereas related events in younger patients occurred across various system organ class designations. CONCLUSIONS: Elderly patients with C1-INH-HAE were significantly older at diagnosis and had greater delay in diagnosis than younger patients. Elderly patients contributed to approximately 10% of the icatibant-treated attacks. Our analysis found similar AE rates (overall and possibly/probably related) in icatibant-treated elderly versus younger patients, despite the fact that elderly patients had significantly more comorbidities and were receiving a greater number of concomitant medications. Our analysis did not identify any new or unexpected safety concerns

Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey.

Funder: Takeda Pharmaceuticals International AG, Zurich, SwitzerlandBACKGROUND: Hereditary angioedema due to C1 inhibitor deficiency (HAE-1/2) is a chronic and debilitating disease. The unpredictable clinical course represents a significant patient burden. OBJECTIVE: To analyse longitudinal registry data from the Icatibant Outcome Survey (IOS) in order to characterize temporal changes in disease activity in patients with HAE-1/2. METHODS: Icatibant Outcome Survey (NCT01034969) is an international observational registry monitoring the clinical outcomes of patients eligible for icatibant treatment. The current analyses are based on data collected between July 2009 and July 2019. Retrospective data for attacks recorded in the 12 months prior to IOS enrolment and for each 12-month period up to 7 years were analysed. RESULTS: Included patients reported angioedema attacks without long-term prophylaxis (LTP; n = 315) and with LTP (n = 292) use at the time of attack onset. Androgens were the most frequently used LTP option (80.8%). At the population level, regardless of LTP use, most patients (52-80%) reporting <5 attacks in Year 1 continued experiencing this rate; similarly, many patients (25-76%) who reported high attack frequency continued reporting ≥10 attacks/year. However, year on year, 31-51% of patients experienced notable changes (increase/decrease of ≥5 attacks) in annual attack frequency. Of patients who reported an absolute change of ≥10 attacks from Year 1 to 2, 17-50% continued to experience a change of this magnitude in subsequent years. CONCLUSION: At the population level, attack frequency was generally consistent over 7 years. At the small group level, 28.8-34.5% of patients reported a change in attack frequency of ≥5 attacks from Year 1 to Year 2; up to half of these patients continued to experience this magnitude of variation in disease activity in later years, reflecting high intra-patient variability

A lightweight framework for secure life-logging in smart environments

As the world becomes an interconnected network where objects and humans interact with each other, new challenges and threats appear in the ecosystem. In this interconnected world, smart objects have an important role in giving users the chance for life-logging in smart environments. However, smart devices have several limitations with regards to memory, resources and computation power, hindering the opportunity to apply well-established security algorithms and techniques for secure life-logging on the Internet of Things (IoT) domain. The need for secure and trustworthy life-logging in smart environments is vital, thus, a lightweight approach has to be considered to overcome the constraints of smart objects. The purpose of this paper is to present in details the current topics of life-logging in smart environments, while describing interconnection issues, security threats and suggesting a lightweight framework for ensuring security, privacy and trustworthy life-logging. In order to investigate the efficiency of the lightweight framework and the impact of the security attacks on energy consumption, an experimental test-bed was developed including two interconnected users and one smart attacker, who attempts to intercept transmitted messages or interfere with the communication link. Several mitigation factors, such as power control, channel assignment and AES-128 encryption were pplied for secure life-logging. Finally, research into the degradation of the consumed energy regarding the described intrusions is presented